Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07439172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

Study acronym: PRC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Mar 2026 to Jul 13, 2026 · Eligibility criteria expanded, about 17 words Show 2 more changesShow less
    • Start date changed from estimate of Mar 2026 to Jul 13, 2026
    • Eligibility criteria expanded, about 17 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well. After radiation, MRI scans can be harder to understand because radiation changes how the brain looks on the scan. If new medicines are given before radiation, the scans are easier to read. First, the investigators need to find out if giving chemotherapy early works using a drug we already know can treat gliomas. The investigators will start with temozolomide, which is the only chemotherapy approved by the FDA for HGG. If this approach is successful, the investigators can then test new drugs using this screening method.
Trial Details
NCT Number NCT07439172
Lead Sponsor The Cooper Health System
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Virginia, Virginia Commonwealth University, Wake Forest University, Georgetown University, Musella Foundation, Imaging Biometrics, LLC, West Virginia University
Conditions High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov